The New England journal of medicine
The most recent articles from:
N. Engl. J. Med.
-
Whether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear. ⋯ In this trial involving patients with clinically node-negative, T1 or T2 invasive breast cancer (90% with clinical T1 cancer and 79% with pathological T1 cancer), omission of surgical axillary staging was noninferior to sentinel-lymph-node biopsy after a median follow-up of 6 years. (Funded by the German Cancer Aid; INSEMA ClinicalTrials.gov number, NCT02466737.).